RGEN Logo

Repligen Corporation (RGEN) 

NASDAQ
Market Cap
$8.16B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
130 of 776
Rank in Industry
9 of 48

Largest Insider Buys in Sector

RGEN Stock Price History Chart

RGEN Stock Performance

About Repligen Corporation

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput …

Insider Activity of Repligen Corporation

Over the last 12 months, insiders at Repligen Corporation have bought $600,476 and sold $14.08M worth of Repligen Corporation stock.

On average, over the past 5 years, insiders at Repligen Corporation have bought $316,041 and sold $21.15M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Madaus Martin D (director) — $605,328. BARTHELEMY NICOLAS (director) — $451,620. Hunt Anthony (Chief Executive Officer) — $248,160.

The last purchase of 1,615 shares for transaction amount of $201,776 was made by Madaus Martin D (director) on 2024‑06‑14.

List of Insider Buy and Sell Transactions, Repligen Corporation

2024-09-10Saledirector
22,191
0.0393%
$145.37$3.23M-4.57%
2024-08-02SaleSenior VP, R&D
7,148
0.0126%
$159.35$1.14M-10.47%
2024-08-01SaleSenior VP, R&D
4,465
0.008%
$165.67$739,717-12.49%
2024-06-14PurchaseChief Executive Officer
2,000
0.0032%
$124.08$248,160+13.06%
2024-06-14Purchasedirector
1,200
0.0019%
$125.45$150,540+13.06%
2024-06-14Purchasedirector
1,615
0.0026%
$124.94$201,776+13.06%
2024-05-21SaleChief Executive Officer
20,072
0.0362%
$168.26$3.38M-14.24%
2024-03-11SaleSenior VP, R&D
3,517
0.0063%
$193.73$681,348-22.05%
2024-03-08SaleChief Executive Officer
16,707
0.0302%
$197.44$3.3M-22.83%
2024-02-27Saledirector
1,000
0.0018%
$193.35$193,350-20.63%
2024-02-23SaleChief Operating Officer
4,373
0.0079%
$198.08$866,204-21.73%
2023-11-10SaleSee Remarks
3,788
0.0068%
$147.13$557,328+11.09%
2023-08-29Saledirector
850
0.0015%
$171.38$145,673-4.37%
2023-05-08Purchasedirector
500
0.0009%
$156.18$78,090+6.26%
2023-05-05Purchasedirector
500
0.0009%
$159.19$79,595+3.85%
2023-05-04Purchasedirector
500
0.0009%
$161.15$80,575+5.78%
2023-02-16SaleChief Financial Officer
5,647
0.0103%
$200.00$1.13M-16.55%
2022-11-11SaleChief Executive Officer
25,000
0.0452%
$200.00$5M-16.33%
2022-09-09Sale
775
0.0014%
$227.17$176,057-26.55%
2022-09-08SaleChief Executive Officer
6,626
0.0118%
$224.47$1.49M-24.48%

Insider Historical Profitability

15.28%
Hunt Anthonydirector
139840
0.2497%
$145.71127
DAWES KAREN Adirector
87367
0.156%
$145.71521+21.46%
BARTHELEMY NICOLASdirector
4668
0.0083%
$145.7117
Madaus Martin Ddirector
4613
0.0082%
$145.7140+5.3%
HERLIHY WALTER CPRESIDENT, CEO
262430
0.4686%
$145.71115+58.42%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$1.43B13.917.77M-1.1%-$15.91M0.03
The Vanguard Group$937.99M9.135.1M+0.43%+$3.99M0.02
T. Rowe Price$656.29M6.393.57M-11.02%-$81.28M0.08
Fidelity Investments$415.25M4.042.26M+19.93%+$69.02M0.03
State Street$323.37M3.151.76M+3.21%+$10.04M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.